As Pfizer began its pursuit of delivering two biosimilar monoclonal antibodies (mAbs) in China, it sought a partner that could mitigate the risks of expanding into this region while also significantly reducing the development timeline. By leveraging the expertise of an experienced partner and the benefits of single-use technology (SUT), Pfizer was able to quickly establish a global footprint while also gaining a competitive advantage in an emerging market.
Scaling up a bioprocess doesn’t need to be a headache – especially when there are firms out there that can lend a helping hand.
One solution to drug development challenges is adopting a parallel operations business model. This article provides several recommendations for how parallel operations can be leveraged in your biomanufacturing strategy.
By checking the pulse of your organization, you can identify gaps and develop a plan for how to address them, so you can make the right decisions at the right time.
How an integrated development platform can provide end-to-end visibility across pre-formulations and formulations development.
How to overcome the challenges the shift from internal to external, or virtual, R&D teams poses.
A solution designed to provide a working environment that is easy to use across multiple disciplines to meet the full range of scientific needs.
An easy two-step protocol to purify adenoviruses.
Finding ways to optimize the holistic preclinical development.
Tips for having a more cohesive workforce resulting in a team that pushes the boundaries of research innovation.